Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues.

Abstract excerpt

Clinical use of polygenic risk scores (PRS) will look very different to the more familiar monogenic testing. Here we argue that despite these differences, most of the ethical, legal, and social issues (ELSI) raised in the monogenic setting, such as the relevance of results to family members, the approach to secondary and incidental findings, and the role of expert mediators, continue to be relevant in the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers
• Share to BRCA gene mutations in cancer
• Share to Ethics, Medical